Journal ArticleOPEN ACCESS

Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

Open Forum Infectious Diseases (2024) 11(3)
DOI: 10.1093/ofid/ofae070
8Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.

Author supplied keywords

Cite

CITATION STYLE

APA

Streifel, A. C., Strnad, L. C., Sikka, M. K., Varley, C. D., Makadia, J., Sukerman, E., … LewisII, J. S. (2024). Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis. Open Forum Infectious Diseases, 11(3). https://doi.org/10.1093/ofid/ofae070

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free